Development of medical termination of pregnancy: a review. (27th September 2017)

• Record Type: Journal Article
• Authors: Ho, PC
• Is Part Of: BJOG. Volume 124:Number 13(2017)
• Page Start: 1942
• Page End: 1947
• Publication Date: 2017-09-27
• Subjects: Mifepristone -- misoprostol -- termination of pregnancy; Obstetrics -- Periodicals; Gynecology -- Periodicals; 618
• DOI: 10.1111/1471-0528.14905
• Languages: English
• ISSNs: 1470-0328

Abstract

Abstract : The synthesis of mifepristone, an antiprogestin blocking the action of progesterone at the receptor level, started a new era of medical termination of pregnancy (MTOP). The initial results of MTOP with mifepristone alone were disappointing; however, mifepristone can sensitise the myometrium to the action of prostaglandins. Clinical trials have shown that the sequential administration of mifepristone followed 1–2 days later by a prostaglandin analogue is a safe, effective, and acceptable method for MTOP. This article will review the events and challenges leading to the development of the current evidence‐based and yet off‐label regimen for first‐trimester MTOP. Tweetable abstract: This article reviews the events and challenges in the development of medical termination of pregnancy. Tweetable abstract: This article reviews the events and challenges in the development of medical termination of pregnancy.